FOR USE IN RHEUMATOLOGY AND GASTROENTEROLOGYSulfasalazine Shared Care Agreement • June 22nd, 2020
SPECIALIST RESPONSIBILITIES 1. Assess patient, confirm diagnosis and discuss benefits and risks of treatment with the patient.2. Perform pre-treatment assessments and on-going monitoring as detailed on page 3.3. Prescribers should familiarise themselves with the drug indication, dose, administration, contra-indications, cautions, side-effects, interactions and preparation by referring to the current version of the Summary of Product Characteristics (https://www.medicines.org.uk/emc/product/6686/smpc) or the BNF (http://www.medicinescomplete.com/mc/index.htm).4. Initiate and titrate treatment with sulfasalazine therapy and supply until dose and monitoring stable for 6 weeks.5. Provide appropriate written information on sulfasalazine to the patient.6. Review efficacy of treatment and ensure any drug treatment changes are communicated to the GP.7. Act on pathology lab results if initiated by the hospital.8. Advise the GP on frequency of monitoring and what to do when the parameters change
SULFASALAZINE SHARED CARE AGREEMENT (SCA)Sulfasalazine Shared Care Agreement • March 24th, 2015
SPECIALIST RESPONSIBILITIES 1. Assess patient, confirm diagnosis and discuss benefits and risks of treatment with the patient.2. Perform pre-treatment assessments and on-going monitoring as detailed on page 2.3. Initiate, titrate and stabilise the patient on treatment with oral sulfasalazine. Prescribers should familiarise themselves with the drug indication, dose, administration, contra-indications, cautions, side-effects, interactions and preparation by referring to the current version of the Summary of Product Characteristics (http://www.medicines.org.uk/emc/default.aspx) or the BNF/BNF for Children (http://www.medicinescomplete.com/mc/index.htm).4. Provide appropriate written information on sulfasalazine to the patient.5. Discuss proposed SCA with the patient and explain that their GP may or may not wish to participate. The patient has the choice to continue receiving treatment solely from the specialist if they wish.6. Send a letter to the patient’s GP to request participation in
Sulfasalazine Shared Care AgreementSulfasalazine Shared Care Agreement • December 10th, 2019
Patient’s Name: NHS Number: Date of Birth: Date Treatment Started: Copy of information given to patient Copy of agreement to general practitioner Name of Initiating Nurse Specialist / Doctor: Consultant:Speciality: RHEUMATOLOGY Email: trauma.ortho@nhs.net
FOR USE IN RHEUMATOLOGY AND GASTROENTEROLOGYSulfasalazine Shared Care Agreement • June 25th, 2020
SPECIALIST RESPONSIBILITIES 1. Assess patient, confirm diagnosis and discuss benefits and risks of treatment with the patient.2. Perform pre-treatment assessments and on-going monitoring as detailed on page 3.3. Prescribers should familiarise themselves with the drug indication, dose, administration, contra-indications, cautions, side-effects, interactions and preparation by referring to the current version of the Summary of Product Characteristics (https://www.medicines.org.uk/emc/product/6686/smpc) or the BNF (http://www.medicinescomplete.com/mc/index.htm).4. Initiate and titrate treatment with sulfasalazine therapy and supply until dose and monitoring stable for 6 weeks.5. Provide appropriate written information on sulfasalazine to the patient.6. Review efficacy of treatment and ensure any drug treatment changes are communicated to the GP.7. Act on pathology lab results if initiated by the hospital.8. Advise the GP on frequency of monitoring and what to do when the parameters change
